World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)

Questions: Discounts, Updates etc.

Pages: 230

Price (Single): $4500

Price (Company): $9000

Publication Date: 2010-07-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


What Will The Pharmaceutical Market Look Like in the Next Five Years?

This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in pharmaceuticals, the companies that produce the lion's share of revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of companies and the lines between pharmaceutical and biotechnology specialty companies are becoming more blended; which is a trend expected to continue to grow.

The World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.

 

Biopharma and Pharma: The Line Becomes Blurred

The line between pharmaceutical companies and biopharmaceutical companies is blurred to the point of no longer being a distinct. Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years - Pfizer, Merck and Novartis. These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies. The result of all interest in biological solutions to major diseases? In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact.

Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses.

The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

 

Key Issues and Trends in the Industry

Issues and Trends discussed in this report include:

Also, despite an in-depth interview process and complete review of company financials, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical and biopharmaceutical sales are not discussed.

This report presents an accurate picture of the marketplace today, including

This report is based on review of government filings and company literature, but also interviews with executives and experts, and the perspective of an analyst who has authored scores of reports in this industry.

 

Late Stage Product Development of the Top 50 Companies

50 top companies make up over 90% of the world biopharmaceutical market; The top three companies have nearly a quarter of global sales in 2009.

This report looks at each key player's late-stage pipeline in detail. The top 50 companies discussed in this report include:

 

Table of Contents


TABLE OF CONTENTS

 

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER TWO: INTRODUCTION

CHAPTER THREE: ISSUES AND TRENDS

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

CHAPTER FIVE: COMPANIES OF INTEREST

CHAPTER SIX: MARKET FORECAST

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET

  • Biopharmaceutical Companies
  • Biopharmaceutical Market ForecastAPPENDIX: LIST OF COMPANIES

     

    TABLE OF EXHIBITS

     

    CHAPTER ONE: EXECUTIVE SUMMARY

    • Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated($ in billions)
    • Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated
    CHAPTER TWO: INTRODUCTION
    • Table 2-1: Phases of Clinical Drug Development
    • Table 2-2: Components of a Clinical Trial
    CHAPTER THREE: ISSUES AND TRENDS
    • Table 3-1: International Population Trend Age 65+
    • Figure 3-1: International Population Trend Age 65+
    • Table 3-2: United States Population Trend Age 65+
    • Figure 3-2: International Population Trend Age 65+
    • Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
    • Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
    • Figure 3-3: Drug Development Cost Progression
    • Table 3-5: Total Industry R&D Spending 2004-2009
    • Figure 3-4: Total Industry R&D Spending 2004-2009
    CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
    • Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)
    • Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-3: Pfizer’s Late Stage Product Pipeline
    • Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-3: Merck’s* Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-5: Merck & Co.’s Late Stage Product Pipeline
    • Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-5: Novartis’ Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-7: Novartis’ Late Stage Product Pipeline
    • Figure 4-6: Novartis’ Late Stage Product Pipeline by Therapeutic Area
    • Table 4-8: Roche’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-7: Roche’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-9: Roche’s Late Stage Product Pipeline
    • Figure 4-8: Roche’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-10: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-9: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-11: Sanofi-Aventis’ Late Stage Product Pipeline
    • Figure 4-10: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
    • Table 4-12: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-11: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-13: AstraZeneca’s Late Stage Product Pipeline
    • Figure 4-12: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
    • Table 4-14: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-13: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-15: GlaxoSmithKline’s Late Stage Product Pipeline
    • Figure 4-14: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-15: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
    • Figure 4-16: Johnson & Johnson’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-17: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009
    • Table 4-19: Eli Lilly’s Late Stage Product Pipeline
    • Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-20: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-19: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-21: Bristol-Myers Squibb’s Late Stage Product Pipeline
    • Figure 4-20: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
    • Table 4-22: Abbott’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-21: Abbott’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-23: Abbott’s Late Stage Product Pipeline
    • Figure 4-22: Abbott’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2009(Millions)
    • Figure 4-23: Takeda’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
    • Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-26: Bayer’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-25: Bayer’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-27: Bayer’s Late Stage Product Pipeline
    • Figure 4-26: Bayers’ Late Stage Product Pipeline by Therapeutic Area
    • Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2009(Millions)Figure 4-27: Amgen’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-29: Amgen’s Late Stage Product Pipeline
    • Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Figure 4-29: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
    • Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
    • Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-32: TEVA’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Figure 4-31: TEVA’s Total Company Revenue and R&D Spending 2007-2009(Millions)
    • Table 4-33: TEVA’s Late Stage Product PipelineFigure 4-32: TEVA’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-34: Astellas’ Total Company Revenue and R&D Spending 2007-2009(millions)
    • Figure 4-33: Astellas’ Total Company Revenue and R&D Spending 2007-2009(millions)
    • Table 4-35: Astellas’ Late Stage Product Pipeline
    • Figure 4-34: Astellas’ Late Stage Product Pipeline by Therapeutic Area
    • Table 4-36: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Figure 4-35: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Table 4-37: Daiichi Sankyo’s Late Stage Product Pipeline
    • Figure 4-36: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-38: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Figure 4-37: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)
    • Table 4-39: Novo Nordisk’s Late Stage Product Pipeline
    • Figure 4-38: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
    • Table 4-40: Eisai’s Total Company Revenue and R&D Spending 2007-2009(Thousands)
    • Figure 4-39: Eisai’s Total Company Revenue and R&D Spending 2007-2009
    • Table 4-41: Eisai’s Late Stage Product Pipeline
    • Figure 4-40: Eisai’s Late Stage Product Pipeline by Therapeutic Area
    CHAPTER FIVE: COMPANIES OF INTEREST
    • Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales
    • Table 5-2: Otsuka Pharmaceutical’s Late Stage Product Pipeline
    • Figure 5-1: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-3: Merck KGaA’s Late Stage Product Pipeline
    • Figure 5-2: Merck KGaA’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-4: Gilead Sciences’ Late Stage Product Pipeline
    • Figure 5-3: Gilead Sciences’ Late Stage Product Pipeline by Therapeutic Area
    • Table 5-5: Baxter International’s Late Stage Product Pipeline
    • Figure 5-4: Baxter International’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-6: Chugai Pharmaceutical’s Late Stage Product Pipeline
    • Figure 5-5: Chugai’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-7: Mitsubishi Tanabe’s Late Stage Product Pipeline
    • Figure 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-8: UCB Pharma’s Late Stage Product Pipeline
    • Figure 5-7: UCB’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-9: Allergan’s Late Stage Product Pipeline
    • Figure 5-8: Allergan’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-10: Forest Laboratories’ Late Stage Product Pipeline
    • Figure 5-9: Forest Laboratories’ Late Stage Product Pipeline by Therapeutic Area
    • Table 5-11: Nycomed’s Late Stage Product Pipeline
    • Figure 5-10: Nycomed’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-12: Genzyme’s Late Stage Product Pipeline
    • Figure 5-11: Genzyme’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-13: Biogen Idec’s Late Stage Product Pipeline
    • Figure 5-12: Biogen Idec’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-14: Hospira’s Late Stage Product Pipeline
    • Figure 5-13: Hospira’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-15: CSL’s Late Stage Product Pipeline
    • Figure 5-14: CSL’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-16: Alcon’s Late Stage Product Pipeline
    • Figure 5-15: Alcon’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-17: Shire’s Late Stage Product Pipeline
    • Figure 5-16: Shire’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-18: Celgene’s Late Stage Product Pipeline
    • Figure 5-17: Celgene’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-19: Lundbeck’s Late Stage Product Pipeline
    • Figure 5-18: Lundbeck’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-20: Shionogi’s Late Stage Product Pipeline
    • Figure 5-19: Shionogi’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-21: Menarini’s Late Stage Product Pipeline
    • Figure 5-20: Menarini’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-22: Dainippon Sumitomo’s Late Stage Product Pipeline
    • Figure 5-21: Dainippon Sumitomo’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-23: Cephalon’s Late Stage Product Pipeline
    • Figure 5-22: Cephalon’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-24: Actelion’s Late Stage Product Pipeline
    • Figure 5-23: Actelion’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-25: Endo Pharmaceutical’s Late Stage Product Pipeline
    • Figure 5-24: Endo Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-26: Ono Pharmaceutical’s Late Stage Product Pipeline
    • Figure 5-25: Ono Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
    • Table 5-27: Purdue Pharma’s Late Stage Product Pipeline
    • Figure 5-26: Purdue Pharma’s Late Stage Product Pipeline by Therapeutic Area
    CHAPTER SIX: MARKET FORECAST
    • Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)
    • Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
    • Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
    • Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
    • Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
    • Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)
    • Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment2005-2010
    • Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
    • Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated
    • Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—Potential Impact from Late-Stage Development
    • Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact from Late-Stage Development
    CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
    • Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales
    • Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues
    • Table 7-3: Biotechnology Late Stage Development Projects by Company Classification—Pharmaceutical vs. Biotechnology--Market Forecast, 2015

    • Other users found this report page using the following search terms: pharmaceutical 2010 market top world global pharma biopharmaceutical pipeline rd

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.